Cyproheptadine
| Clinical data | |
|---|---|
| Pronunciation | /ˌsaɪproʊˈhɛptədiːn/ |
| Trade names | Periactin, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682541 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 96 to 99% |
| Metabolism | Liver, mostly CYP3A4 mediated. |
| Elimination half-life | 8.6 hours |
| Excretion | Faecal (2–20%; of which, 34% as unchanged drug) and renal (40%; none as unchanged drug) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.004.482 |
| Chemical and physical data | |
| Formula | C21H21N |
| Molar mass | 287.406 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Cyproheptadine, sold under the brand name Periactin among others, is a first-generation antihistamine with additional anticholinergic, antiserotonergic, and local anesthetic properties.
It was patented in 1959 and came into medical use in 1961. In 2022, it was the 293rd most commonly prescribed medication in the United States, with more than 400,000 prescriptions.